Poxel
Biopharma developing treatments for metabolic diseases like NASH, with a marketed drug for diabetes.
POXEL | PA
Overview
Corporate Details
- ISIN(s):
- FR0012432516
- LEI:
- 9695003OIX0T7NX72N26
- Country:
- France
- Address:
- 259 AVENUE JEAN JAURES, 69007 LYON
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Poxel SA is a clinical-stage biopharmaceutical company developing treatments for metabolic diseases, with a focus on non-alcoholic steatohepatitis (NASH) and rare metabolic disorders. Its pipeline features two mid-stage candidates: PXL065 (deuterium-stabilized R-pioglitazone) for NASH, which met its primary endpoint in a Phase 2 trial, and PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator for rare diseases. The company's product, TWYMEEG® (Imeglimin), was approved in 2021 and is marketed for type 2 diabetes in Japan by its partner Sumitomo Pharma, providing Poxel with royalties and sales-based payments.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Poxel and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-08 17:45 |
Delisting Announcement
Inside Information / Other news releases
|
English | 109.8 KB | |
| 2025-08-08 17:45 |
Legal Proceedings Report
Informations privilégiées / Autres communiqués
|
French | 96.7 KB | |
| 2025-08-01 07:30 |
Legal Proceedings Report
Inside Information / Other news releases
|
English | 134.8 KB | |
| 2025-08-01 07:30 |
Board/Management Information
Informations privilégiées / Autres communiqués
|
French | 164.3 KB | |
| 2025-07-08 18:46 |
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 110.8 KB | |
| 2025-06-30 18:32 |
Pre-Annual General Meeting Information
Inside Information / Other news releases
|
English | 109.4 KB | |
| 2025-06-30 18:32 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 95.0 KB | |
| 2025-06-06 19:05 |
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 76.2 KB | |
| 2025-05-28 07:30 |
Earnings Release
Inside Information / Other news releases
|
English | 95.0 KB | |
| 2025-05-28 07:30 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 119.8 KB | |
| 2025-05-26 18:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 98.0 KB | |
| 2025-05-26 18:00 |
Environmental & Social Information
Informations privilégiées / Autres communiqués
|
French | 86.7 KB | |
| 2025-05-13 07:30 |
Earnings Release
Informations privilégiées / Information sur chiffre d’affaires annuel
|
French | 153.8 KB | |
| 2025-05-13 07:30 |
Earnings Release
Inside Information / Information on annual revenues
|
English | 130.6 KB | |
| 2025-05-06 17:45 |
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 84.4 KB |
Automate Your Workflow. Get a real-time feed of all Poxel filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Poxel via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-29 | N/A | Other | Buy | 80,000 | N/A |
